Dr Niels Reinmuth did his medical training at the University of Muenster, Germany, from 1990–1997. In 1998 he completed his doctoral thesis on “A prospective study on prognostic factors in non-small cell lung cancer”. Between 1997-1999 he started his medical residency at the University Hospital Bergmannsheil, Bochum, Germany, which was then interrupted for a postdoctoral fellowship at the Department of Cancer Biology at the UT M.D.Anderson Cancer Center, Houston, Texas,  until the end of 2001. In 2002, Niels Reinmuth continued his residency at the Department of Medicine/Haematology and Oncology, University of Muenster, Germany. In 2005 he moved to the Thoraxklinik Heidelberg, Department of Thoracic Oncology, University of Heidelberg, Germany.

After passing his board certifications for “General Medicine”, “Haematology and General Oncology”, and “Pneumology” in 2007, 2008, and 2010, respectively, he was appointed Senior Physician. Moreover, he was awarded a post-doctoral lecturing qualification by the University of Heidelberg, Germany.

From 2012 until February 2016, Niels Reinmuth worked as Senior Physician at the Lung Clinic Grosshansdorf, Department of Thoracic Oncology, Grosshansdorf, Germany.

Since March 2016, Niels Reinmuth has been leading the Thoracic Oncology Department at the Asklepios Lung Clinic in Munich-Gauting, Germany. 

Dr Reinmuth has been a Co-Principal Investigator (Co-PI) in clinical trials since 1997. In 2006 he co-designed the biomarker programme of a national clinical phase II study. Starting from 2012, his involvement into conducting clinical trials has increased to a major extent, and now he is also acting as PI in various trials. His main interests are targeted therapies in non-small-cell lung cancer, new approaches in small-cell lung cancer and modern therapies in malignant pleural mesothelioma, as well as translational research related to predictive markers.

Dr Reinmuth is member of the German Cancer Society, the German Society of Pulmonology, the International Association for the Study of Lung Cancer (IASLC), the European Society for Medical Oncology (ESMO) and the American Society of Clinical Oncology (ASCO).